

References for US patents and expiries listed in Table 1.		
Drug Name	Patent Numbers	References
Imatinib (Glivec/Gleevec)	US5521184, US6894051, US7544799, USRE43932	[1,2]
Erlotinib (Tarceva)	US5747498, US6900221, USRE41065	[3,4]
sorafenib (Nexavar)	US7235576, US7351834 US8877933	[5,6]
lapatinib (Tyverb/Tykerb)	US6391874, US6713485, US6727256, US7157466, US8513262, US8821927	[7,8]

References for EU patents and expiries listed in Table 1.		
Drug Name	Number	References
Imatinib (Glivec/Gleevec)	EP1047694A1, EP1047694B1, EP1454907A1, EP1454907B1, EP1460072A1, EP1460072B1	[2,9]
Erlotinib (Tarceva)	EP1233948A1, EP1233948A4, EP1233948B1, EP2168581A2, EP2168581A3,	[4,10]

	EP2168581A9, EP2292233A2, EP2292233A3,	
sorafenib (Nexavar)	EP2419103A1, EP1797038A1, EP1797038B1,	[6,11,12]
lapatinib (Tyverb/Tykerb)	EP1294715A1, EP1294715B1, EP2550269A1, EP2550269A4,	[8,13,14]

References for Indian court decisions.

Drug	References
Imatinib (Glivec/Gleevec):	[15]
Erlotinib (Tarceva)	[16]
sorafenib (Nexavar)	[17]
lapatinib (Tyverb/Tykerb)	[18]

References

- 1 FDA Orange Book. Application Number: 021588.
- 2 Novartis. Novartis Annual Report. 2013.<http://www.novartis.com/downloads/investors/reports/novartis-annual-report-2013-en.pdf> (accessed 3 Jun 2015).
- 3 FDA Orange Book. Application Number: 021743.
- 4 OSI Pharmaceuticals. OSI Pharmaceuticals announces patent term extension for Tarceva® (erlotinib). 2007.<http://www.sec.gov/Archives/edgar/data/729922/000095012307013484/y40425exv99w3.htm> (accessed 3 Jun 2015)
- 5 FDA Orange Book. Application Number: 021923.
- 6 Bayer. Bayer Annual Report. 2013.
- 7 FDA Orange Book. Application Number: 022059.
- 8 GlaxoSmithKline. GSK Annual Report. 2013.
<http://www.gsk.com/media/325156/annual-report-2013.pdf> (accessed 3 Jun 2015)
- 9 Carter MC, Cockerill GS, Lackey KE. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. 2013.
- 10 Norris T, Raggon JW, Connell RD, *et al.* Crystalline polymorph of erlotinib hydrochloride; synthesis; treating cancer. 2005.
- 11 马西莫詹尼亚历山德罗, 卡洛-斯特拉卡尔梅洛. Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability. 2012.
- 12 Grunenberg A, Lenz J. Thermodynamically stable form of bay 43-9006 tosylate. 2006.
- 13 Chen YF, Henschke JP, Liu Y, *et al.* Process and intermediates for preparing lapatinib. 2011.
- 14 McClure MS, Osterhout MH, Roschangar F, *et al.* Quinazoline ditosylate salt compounds. 2007.
- 15 Alam A, Desai RP. Civil appeal Nos. 2706-2716 of 2013 with civil appeal No. 2728 of 2013 and civil appeal Nos. 2717-2727 of 2013. 2013. <http://judis.nic.in/supremecourt/imgs1.aspx?filename=40212> (accessed 3 Jun 2015)
- 16 Mukherjee R. Roche-Cipla patent row mediation fails. The Times of India. 2014.<http://timesofindia.indiatimes.com/business/india->

business/Roche-Cipla-patent-row-mediation-fails/articleshow/44989430.cms (accessed 3 Jun 2015)

- 17 Kurian P. Application for compulsory licence under section 84(1) of the Patents Act, 1970 in respect of patent no.215758. 2011.
http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf
(accessed 3 Jun 2015)
- 18 Sridevan P, Parmar D. ORA/22/2011/PT/KOL and M.P. NO.140/2012 in ORA/22/2011/PT/KOL.
<https://www.pharmamedtechbi.com/~media/Supporting Documents/Pharmasia News/2013/August/GSK%20Fresenius%20IPAB Order%201%20%20Aug%201%202013.pdf> (accessed 3 Jun 2015)